Babson Diagnostics (Babson), a transformative medical technology company, today announced the closing of $13. 7 million in cumulative Series A funding provided by Siemens Healthineers, Prism Ventures, Genesis Merchant Capital and Lago Consulting Group
Originally incubated at Siemens Healthineers and developed in partnership with Becton Dickinson, Babson’s disruptive technology is designed to analyze capillary blood samples using only one-tenth of the volume typically collected with venipuncture without sacrificing quality, accuracy or small width, all from a simple finger stick.
“With our strategic partnerships, clinical studies and research and development programs in place with key retail partners, this funding moves our company to a crucial phase of commercialization,” said Eric Olson, founder of Babson. “Together with our growing team and a strong network of strategic partners, we will realize our mission to improve the health of our customers by making diagnostic blood tests more convenient, accessible and humane. “That’s right.
Babson plans to deploy its proprietary technology ecosystem to accessible retail locations – such as pharmacy counters – across the country, giving customers the benefit of longer hours of operation, low out-of-pocket costs, and more human experience.
“Babson Diagnostics has been incubated within Siemens Healthineers from its earliest days,” said Dr. Deepak Nath, President of Laboratory Diagnostics at Siemens Healthineers “As an innovation and consumer-driven company, we are excited to see that Babson’s work is still rooted in our shared values. The company continues to make great progress in democratizing diagnostic blood tests and contributing to the U Oh, S ‘Fighting the Pandemic COVID-19 “That’s right.
Babson’s first generation SARS-CoV-2 IgG antibody test received an emergency FDA approval in June. The company’s antibody test is offered free of charge to essential front-line pharmacy and grocery workers and is currently being used in clinical studies with leading research centers such as Dell Medical School at the University of Texas at Austin.
Visit www to learn more about Babson. Babbondx Come on,
About Babson Diagnosis
Babson Diagnostics aims to democratize diagnostic blood tests by making it easier, faster and more convenient for customers to routinely monitor and improve their health. Babson’s proprietary technology ecosystem is designed to deliver accurate diagnostic results with more human experience. Based in Austin, Texas, its vision for diagnostic blood testing – built on accuracy, convenience, and accessibility – combines transformative diagnostic technology with a customer-first, retail-focused business model that aims to improve customer health and experience. Prior to commercialization, Babson Diagnostics works with retail pharmacies to validate its technology by conducting clinical studies for peer-reviewed publication. For more information about Babson Diagnostics, please visit www. Babbondx Come on,
Please note that this piece of work originally appeared in English at https://www.vcnewsdaily.com/Babson%20Diagnostics/venture-funding.php. As Investocracy aims to bring global startup news and updates in both English and Japanese to you, it’s important that we attribute original source to you. If you have any questions/concerns please write to us at firstname.lastname@example.org